Omeros, Daiichi expand PDE7 inhibitor deal to include addiction
This article was originally published in Scrip
Executive Summary
Omeros and Daiichi Sankyo have amended their March 2010 partnership to develop phosphodiesterase 7 (PDE7) inhibitors to include addiction and compulsive disorders.